MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
MRD in multiple myeloma: determining response
Uses of MRD in patients with multiple myeloma
CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?
Is immunotherapy cost-effective?